SCHEMBL12422663

SCHEMBL12422663

CNc1nccc(-c2cccnc2Oc2cc(C(=O)Nc3cc(C(F)(F)F)ccc3N(C)[C@H]3CCN(C)C3)c(F)cc2C)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEK Q02763 16/20 0.58
KDR P35968 13/20 0.58
AURKA O14965 5/20 0.50
AURKB Q96GD4 5/20 0.50
TPX2 Q9ULW0 4/20 0.50
ABL1 P00519 2/20 0.50
LCK P06239 2/20 0.50
CSF1R P07333 2/20 0.50
SRC P12931 2/20 0.50
MAPK14 Q16539 2/20 0.50
YES1 P07947 1/20 0.50
KIT P10721 1/20 0.50
EGFR P00533 1/20 0.49
NTRK1 P04629 1/20 0.49
INSR P06213 1/20 0.49
FES P07332 1/20 0.49
LYN P07948 1/20 0.49
RET P07949 1/20 0.49
IGF1R P08069 1/20 0.49
MET P08581 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1264955 1.00 TEK (0.58) TEKKDRAURKAAURKBTPX2
SCHEMBL12422666 1.00 TEK (0.58) TEKKDRAURKAAURKBTPX2
SCHEMBL1264263 0.96 TEK (0.59) TEKKDRAURKAAURKBTPX2
SCHEMBL12895229 0.92 TEK (0.59) TEKKDRAURKAABL1LCK
SCHEMBL12895230 0.92 TEK (0.59) TEKKDRAURKAABL1LCK
SCHEMBL1264123 0.92 TEK (0.59) TEKKDRAURKAABL1LCK
SCHEMBL1265065 0.91 TEK (0.71) TEKKDRAURKAAURKBTPX2
SCHEMBL1265124 0.91 TEK (0.71) TEKKDRAURKAAURKBTPX2
SCHEMBL12422050 0.91 TEK (0.71) TEKKDRAURKAAURKBTPX2
SCHEMBL1265747 0.88 TEK (0.60) TEKKDRAURKAABL1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8476434-B2 Protein kinase modulators and method of use AMGEN INC. (US) 2013-07-02 US disclosed
US-20110201602-A1 PROTEIN KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2011-08-18 US disclosed
US-7880000-B2 N-(5-(1,1- dimethylethyl)-3- isoxazolyl)-4-methyl-3- ((3-(4-pyrimidinyl)-2- pyridinyl)amino)benzamide, used for treating breast cancer or rheumatoid arthritis AMGEN INC. (US) 2011-02-01 US disclosed
US-7880000-B2 N-(5-(1,1- dimethylethyl)-3- isoxazolyl)-4-methyl-3- ((3-(4-pyrimidinyl)-2- pyridinyl)amino)benzamide, used for treating breast cancer or rheumatoid arthritis AMGEN INC. (US) 2011-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201602-A1 PROTEIN KINASE MODULATORS AND METHOD OF USE GRK4, MAP4K5, GRK5 TEK 145/4885KDR 42/4885AURKA 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.